CytoAgents Stock

CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza, and other viral infectious diseases.

Sign up today and learn more about CytoAgents Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About CytoAgents Stock

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation also known as cytokine storm.

Funding History

January 2020$100K
May 2020$1.6M
July 2020$250K
January 2021$50K
March 2021$2.0M
July 2021$100K
August 2021$6.1M
May 2023$7.0M

Management

Founder & CEO

Teresa Whalen

Chief Science Officer

Jodi Craigo

Chief Financial Officer

Roy Prieb

Chief Medical Officer

Arthur P. Bertolino

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo